DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
MWN-AI** Summary
DBV Technologies, a late-stage biopharmaceutical company, is set to present additional findings from the VITESSE Phase 3 study of its VIASKIN® Peanut Patch at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting, scheduled for February 27-March 2, 2026, in Philadelphia. The study focuses on children aged 4-7 and aims to showcase the efficacy and safety of epicutaneous immunotherapy (EPIT) in managing peanut allergies. The presentation will be made by Dr. David Fleischer on February 28, 2026, emphasizing the patch's potential to reeducate the immune system and promote early intervention strategies.
During the meeting, DBV will also host a product theater featuring key experts, including Dr. Hugh Sampson and Dr. Katherine Anagnostou, who will discuss the evolving landscape of EPIT and its implications for pediatric food allergy treatment. DBV Technologies continues to explore the application of its proprietary VIASKIN® technology to provide non-invasive treatment options for food allergies, characterized by a hypersensitive immune response. The patch is designed to deliver small quantities of allergens through the skin, leveraging its immune-tolerizing properties.
The company is intensively working on clinical trials, not only for children aged 4-7 but also for toddlers (1-3 years old) with peanut allergies. With food allergies affecting millions, including young children, DBV's commitment to developing transformative therapies aims to significantly improve patient outcomes in this area. While the path forward is promising, DBV acknowledges the inherent uncertainties in research, development, and regulatory processes. As they navigate these challenges, DBV Technologies remains focused on becoming a leader in the food allergy treatment landscape, marking a potential shift towards safer, more effective management strategies for affected individuals.
MWN-AI** Analysis
DBV Technologies (Euronext: DBV; Nasdaq: DBVT), a biopharmaceutical leader in the field of food allergies, will present additional data from its promising VITESSE Phase 3 study at the upcoming AAAAI 2026 Annual Meeting. This pivotal study focuses on the efficacy of the VIASKIN® Peanut Patch for children aged 4-7 with peanut allergies and is highly anticipated by investors and the healthcare community alike.
The company’s strategy to leverage epicutaneous immunotherapy (EPIT) offers a non-invasive treatment method that could reshape the management of peanut allergies, which affect millions globally. The VITESSE study results are expected to further validate the safety and effectiveness of the VIASKIN® Peanut Patch, potentially paving the way for regulatory approval in the U.S. and Europe.
Investors should be acutely aware of the broader implications of this presentation. Successful results from the VITESSE trial could lead to significant commercial opportunities, as the demand for effective allergy therapies is rising. The ability of the VIASKIN® patch to desensitize patients to allergens through the skin's immune properties may shift treatment protocols and allow earlier interventions, which is crucial given the increasing prevalence of food allergies in children.
Market sentiment around the stock may experience fluctuations leading up to and following the AAAAI meeting, particularly if data shared shines a favorable light on the product's efficacy and safety profile. It may also enhance DBV’s negotiations with potential partners and investors.
It is prudent for investors to monitor the clinical developments closely while considering the inherent risks, including regulatory hurdles and market competition. In summary, DBV Technologies is positioned within a critical transformation in allergy management, making it a company to watch in 2026 and beyond.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Châtillon, France, February 10, 2026
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the company will present additional data for the VIASKIN® Peanut Patch in children ages 4-7 years from the positive VITESSE Phase 3 study at the American Academy of Allergy, Asthma, and Immunology 2026 Annual Meeting, taking place in Philadelphia, PA February 27-March 2, 2026.
The Company will also host a product theatre featuring a panel of renowned allergists discussing the potential of epicutaneous immunotherapy (EPIT) to reeducate the immune system in food allergy, examine the impact of early intervention in children with peanut allergy, and consider how emerging treatment options are enabling for a more proactive approach to peanut allergy management.
Oral Abstract Presentation Details
“VITESSE Phase 3 Study: Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children 4 Through 7 Years of Age”
- Session: Clinical Science in Food Allergy
- Date and Time: February 28, 2026, 2:15-2:25pm ET
- Location: Level 4, Terrace Ballroom II
- Presenter: David Fleischer, MD, FAAAAI, FACAAI
Product Theater Details
“Epicutaneous Immunotherapy (EPIT): Shaping the Future of Pediatric Food Allergy Treatment”
- Date and Time: February 28, 2026, 10:00-10:30am ET
- Location: Level 2, Hall E
- Participants: Hugh Sampson, MD, Katherine Anagnostou, MD, MSc, PhD, S. Shahzad Mustafa, MD
DBV will exhibit at booth #1527 in the AAAAI exhibit hall where attendees can learn more about epicutaneous immunotherapy and the VIASKIN® Peanut Patch.
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of VIASKIN® Peanut patch and EPIT, results of DBV’s clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, plans and expectations with respect to the submission of BLAs to FDA, and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 11, 2025, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 28, 2025, and as amended further by Amendment No. 2 on Form 10-K/A filed with the SEC on May 14, 2025, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.
VIASKIN is a registered trademark of DBV Technologies.
Investor Relations Contact
Jonathan Neely
DBV Technologies
[email protected]
Media Contact
Brett Whelan
DBV Technologies
[email protected]
Attachment
FAQ**
How does DBV Technologies plan to leverage the data from the VITESSE Phase 3 study to enhance investor confidence in its VIASKIN® Peanut Patch, especially in light of competitive products like "Dbv Techs Boulogne Bill DBVTF"?
What specific strategies will DBV Technologies employ to address regulatory challenges regarding the VIASKIN® Peanut Patch, and how might these relate to advancements in "Dbv Techs Boulogne Bill DBVTF"?
Can DBV Technologies articulate the anticipated market impact of its findings from the VITESSE Phase 3 study, considering the growing interest in EPIT therapies like "Dbv Techs Boulogne Bill DBVTF"?
How will the upcoming presentation at the AAAAI Annual Meeting contribute to the broader narrative around food allergy treatment options, particularly in contrast to therapies represented by "Dbv Techs Boulogne Bill DBVTF"?
**MWN-AI FAQ is based on asking OpenAI questions about DBV Technologies S.A. (NASDAQ: DBVT).
NASDAQ: DBVT
DBVT Trading
-3.69% G/L:
$20.71 Last:
174,244 Volume:
$22.02 Open:
